1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Kaufman DS, Shipley WU and Feldman AS:
Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Pryor WA: Cigarette smoke radicals and the
role of free radicals in chemical carcinogenicity. Environ Health
Perspect. 105(Suppl 4): 875–882. 1997. View Article : Google Scholar : PubMed/NCBI
|
4
|
Franekova M, Halasova E, Bukovska E, et
al: Gene polymorphisms in bladder cancer. Urol Oncol. 26:1–8. 2008.
View Article : Google Scholar
|
5
|
Murray AW: Recycling the cell cycle:
cyclins revisited. Cell. 116:221–234. 2004. View Article : Google Scholar : PubMed/NCBI
|
6
|
Santamaria D and Ortega S: Cyclins and
CDKS in development and cancer: lessons from genetically modified
mice. Front Biosci. 11:1164–1188. 2006. View Article : Google Scholar : PubMed/NCBI
|
7
|
Meyerson M and Harlow E: Identification of
G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell
Biol. 14:2077–2086. 1994.PubMed/NCBI
|
8
|
Lee KH, Lotterman C, Karikari C, et al:
Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent
kinase 6 expression in pancreatic cancer. Pancreatology. 9:293–301.
2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Chilosi M, Doglioni C, Yan Z, et al:
Differential expression of cyclin-dependent kinase 6 in cortical
thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am J Pathol.
152:209–217. 1998.PubMed/NCBI
|
10
|
Costello JF, Plass C, Arap W, et al:
Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas
identified using two-dimensional separation of genomic DNA. Cancer
Res. 57:1250–1254. 1997.PubMed/NCBI
|
11
|
Mendrzyk F, Radlwimmer B, Joos S, et al:
Genomic and protein expression profiling identifies CDK6 as novel
independent prognostic marker in medulloblastoma. J Clin Oncol.
23:8853–8862. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Raspollini MR, Nesi G, Baroni G, et al:
p16(INK4a) expression in urinary bladder carcinoma. Arch Ital Urol
Androl. 78:97–100. 2006.PubMed/NCBI
|
13
|
Shariat SF, Tokunaga H, Zhou J, et al:
p53, p21, pRB, and p16 expression predict clinical outcome in
cystectomy with bladder cancer. J Clin Oncol. 22:1014–1024. 2004.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Chen G, Cheng Y, Zhang Z, et al:
Prognostic significance of cytoplasmic p27 expression in human
melanoma. Cancer Epidemiol Biomarkers Prev. 20:2212–2221. 2011.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German).
|
16
|
Rodriguez-Otero P, Roman-Gomez J,
Vilas-Zornoza A, et al: Deregulation of FGFR1 and CDK6 oncogenic
pathways in acute lymphoblastic leukaemia harbouring epigenetic
modifications of the MIR9 family. Br J Haematol. 155:73–83. 2011.
View Article : Google Scholar
|
17
|
Russo AA, Tong L, Lee JO, et al:
Structural basis for inhibition of the cyclin-dependent kinase Cdk6
by the tumour suppressor p16INK4a. Nature. 395:237–243. 1998.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Eissa S, Ahmed MI, Said H, et al: Cell
cycle regulators in bladder cancer: relationship to
schistosomiasis. IUBMB Life. 56:557–564. 2004. View Article : Google Scholar : PubMed/NCBI
|
19
|
Osman HG, Abadeer NY, Mohamed SE and Fahmy
AK: Expression of p16, p15 and Cyclin D1 in bladder cancer and
correlation with cancer progression. Internet J Urol. 4:http://www.ispub.com/journal/the-internet-journal-of-urology/volume-4-number-2/expression-of-p16-p15-and-cyclin-d1-in-bladder-cancer-and-correlates-with-cancer-progression-and-clinical-out-come.html.
|